Literature DB >> 25906688

Expression and Characterization of the Extracellular Domain of Human HER2 from Escherichia Coli, and Production of Polyclonal Antibodies Against the Recombinant Proteins.

Yong Sun1, Xue Feng, Jiao Qu, Wenqi Han, Zi Liu, Xu Li, Ming Zou, Yuhong Zhen, Jie Zhu.   

Abstract

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family. In this study, the whole extracellular domain gene of HER2 was amplified by RT-PCR from human breast cancer cell line SK-BR-3. The genes of membrane-distal region (A) and membrane proximal region (B) of HER2 extracellular domain were amplified from the cloned template, and then inserted into the expression vector pET-28a and pET-30a, respectively. The recombinant expression vectors were transformed into Escherichia coli BL21 (DE3) cells and induced by isopropyl-b-D-thiogalactopyranoside (IPTG) for expression of proteins His-A and His-B. The expressed proteins were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot. The optimization of culture conditions led us to accomplish the recombinant protein induction with 1.0 mM IPTG at 37 °C for 8 h, and both proteins were expressed in the insoluble form. Both proteins were purified under the denaturing condition using Ni-NTA sepharose column. Balb/c mice were immunized with the purified proteins and then effectively produced polyclonal antibodies, which reached to a relatively high titer by ELISA testing and had good specificity by western blot detection. The HER2 ECD proteins His-A and His-B could be expressed in E. coli and were suitable for production of high titer antibodies against HER2 ECD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25906688     DOI: 10.1007/s12010-015-1627-x

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  3 in total

1.  HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.

Authors:  Andreia Gameiro; Catarina Nascimento; Jorge Correia; Fernando Ferreira
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

2.  Production of polyclonal antibody against the recombinant PirBvp protein of Vibrio parahaemolyticus.

Authors:  Ngoc-Diem Duong; Khai-Hoan Nguyen-Phuoc; Kim-Yen Thi Do; Nguyet-Thu Thi Nguyen; Thuoc Linh Tran; Hieu Tran-Van
Journal:  J Genet Eng Biotechnol       Date:  2021-05-11

3.  Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma.

Authors:  Andreia Gameiro; Filipe Almeida; Catarina Nascimento; Jorge Correia; Fernando Ferreira
Journal:  Pharmaceutics       Date:  2021-03-06       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.